{"id":60420,"date":"2024-02-28T06:48:16","date_gmt":"2024-02-28T06:48:16","guid":{"rendered":"https:\/\/medsname.com\/riscon\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"riscon","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/riscon\/","title":{"rendered":"Riscon"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Riscon?<\/h3>\n
\n

Riscon<\/strong> tartalmaz risperidone<\/strong> from a WHO-GMP certified manufacturer (Sun Pharma) — one of the most-prescribed atypical antipsychotics<\/strong> worldwide. FDA-approved for schizophrenia (adults and adolescents 13+), bipolar mania (adults and ages 10+), and irritability in autism (children 5+). Mechanism: tight D2<\/sub> + 5-HT2A<\/sub> antagonism. Standard adult dose: 2–6 mg\/day<\/strong> (start 0.5–1 mg, titrate gradually). Distinctive side effects<\/strong>: highest hyperprolactinaemia<\/strong> of the atypicals (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction); EPS at doses > 6 mg\/day (atypical \u2192 typical “crossover” behaviour); moderate metabolic burden. FDA black box for elderly dementia mortality<\/strong>.<\/p>\n<\/div>\n

\nMit kapsz a MedsBase-n\u00e1l:<\/strong> WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3 \u00b7 Diszkr\u00e9t csomagol\u00e1s \u00b7 Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s \u00b7 1.400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>\n<\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n

Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n

Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n<\/div>\n

Fontos \u2014 ez nem helyzeti szorong\u00e1sra sz\u00e1nt gy\u00f3gyszer.<\/strong> Riscon is a at\u00edpusos antipszichotikumok<\/strong>, hetekig tart\u00f3 fel\u00edr\u00e1ssal \u00e9s adagol\u00e1ssal kezelhet\u0151 schizophrenia, bipolar mania, and irritability associated with autistic disorder in children<\/strong>. Ez nem<\/strong> , a megfelel\u0151 gy\u00f3gyszer akut, teljes\u00edtm\u00e9nyhez kapcsol\u00f3d\u00f3 szorong\u00e1s eset\u00e9n (rep\u00fcl\u00e9s, nyilv\u00e1nos besz\u00e9d, vizsg\u00e1k) \u2014 ezekre az esetekre klinikailag a b\u00e9ta-blokkol\u00f3k (propranolol), benzodiazepinek vagy hydroxyzine alkalmasak. Ha nincs diagnosztiz\u00e1lt hangulati, szorong\u00e1sos vagy pszichi\u00e1triai zavara, ne kezdje el ezt a gy\u00f3gyszert.<\/div>\n
FDA black-box warning — elderly dementia mortality.<\/strong> All antipsychotics (atypical and conventional) carry an FDA black-box warning for increased mortality when used to treat dementia-related psychosis or behavioural disturbance in elderly patients. This medication is nem hagyta j\u00f3v\u00e1<\/strong> for dementia-related symptoms.<\/div>\n

What Is Riscon?<\/h2>\n

Riscon is an oral tablet of risperidone<\/strong> manufactured by Sun Pharma. Risperidone (US brand Risperdal<\/strong>) was launched by Janssen in 1993 and is one of the most-prescribed atypical antipsychotics globally. It is a tight D2<\/sub> \u00e9s 5-HT2A<\/sub> antagonista<\/strong> with additional alpha-1, alpha-2, and H1<\/sub> blockade. Tighter D2<\/sub> binding than other atypicals means risperidone behaves more like a first-generation antipsychotic at higher doses — with EPS risk above 6 mg\/day. The active metabolite paliperidone (9-OH-risperidone) drives much of the clinical effect and is itself marketed separately as Invega.<\/p>\n

J\u00f3v\u00e1hagyott indik\u00e1ci\u00f3k<\/h2>\n
    \n
  • Skizofr\u00e9nia<\/strong> — adults and adolescents (age 13+)<\/li>\n
  • Bipol\u00e1ris m\u00e1nia (akut)<\/strong> — adults and children (age 10+); monotherapy or with lithium \/ valproate<\/li>\n
  • Irritability associated with autistic disorder<\/strong> — children (age 5+); aggression, self-injurious behaviour, severe tantrums<\/li>\n
  • Off-label: behavioural disturbance in dementia (use very carefully — black-box warning), Tourette syndrome, treatment-resistant depression, OCD augmentation<\/li>\n<\/ul>\n

    Adagol\u00e1s<\/h2>\n\n\n\n\n\n\n\n\n\n\n
    Agoprex is a 25 mg agomelatine tablet supplied by Sun Pharma. Agomelatine is mechanistically unique among antidepressants: it acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C serotonin receptors. The dual mechanism resynchronises disrupted circadian rhythms (a feature of major depression) while indirectly increasing dopamine and noradrenaline release in the frontal cortex.<\/th>\nKezel\u00e9s ind\u00edt\u00e1sa<\/th>\nIndications and dosing<\/th>\nMaxim\u00e1lis<\/th>\nMegjegyz\u00e9sek<\/th>\n<\/tr>\n<\/thead>\n
    Skizofr\u00e9nia (feln\u0151tt)<\/td>\n1 mg BID or 2 mg HS<\/td>\n4–8 mg\/day<\/td>\n16 mg\/napra<\/td>\nMost prescribers stay 2–6 mg\/day — EPS risk rises sharply above 6 mg\/day<\/td>\n<\/tr>\n
    Schizophrenia (adolescent 13+)<\/td>\n0.5 mg HS<\/td>\n3 mg\/nap<\/td>\n6 mg\/day<\/td>\nStandard adolescent target<\/td>\n<\/tr>\n
    Bipol\u00e1ris m\u00e1ni\u00e1s epiz\u00f3d (feln\u0151tt)<\/td>\n2–3 mg HS<\/td>\n1–6 mg\/day<\/td>\n6 mg\/day<\/td>\nOnce-daily HS dosing typical<\/td>\n<\/tr>\n
    Autism irritability (5–16 y, < 20 kg)<\/td>\n0.25 mg\/day<\/td>\n0.5–3 mg\/day weight-based<\/td>\n\u2014<\/td>\nSlow titration; reassess after 4–6 weeks<\/td>\n<\/tr>\n
    Id\u0151s<\/td>\n0.25–0.5 mg BID<\/td>\n1–2 mg\/day<\/td>\n\u2014<\/td>\nSignificant orthostasis and falls risk; black-box dementia warning<\/td>\n<\/tr>\n
    M\u00e1ji\/veseel\u00e9gtelens\u00e9g<\/td>\n0.5 mg BID<\/td>\nLassabb d\u00f3zisemel\u00e9s<\/td>\n\u2014<\/td>\nHalve usual dose increments<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Mell\u00e9khat\u00e1sok<\/h2>\n

    Side-effect profile<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Gyakoris\u00e1g<\/th>\nHat\u00e1s<\/th>\nMegjegyz\u00e9sek<\/th>\n<\/tr>\n<\/thead>\n
    Gyakori<\/td>\nHyperprolaktinaemia<\/td>\nHighest of the atypicals — galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction; check prolactin if symptomatic<\/td>\n<\/tr>\n
    Gyakori<\/td>\nSedation, fatigue<\/td>\nModerate; less than quetiapine<\/td>\n<\/tr>\n
    Gyakori<\/td>\nS\u00falygyarapod\u00e1s<\/td>\nModerate (3–5 kg over 12 months)<\/td>\n<\/tr>\n
    Gyakori<\/td>\nOrtosztatikus hypot\u00f3nia<\/td>\nAlfa-1 blok\u00e1d<\/td>\n<\/tr>\n
    Common (dose-dependent)<\/td>\nExtrapyramidal symptoms (akathisia, parkinsonism, dystonia)<\/td>\nHigher than other atypicals; significant above 6 mg\/day<\/td>\n<\/tr>\n
    Gyakori<\/td>\nAnticholinergic (dry mouth, constipation)<\/td>\nEnyhe<\/td>\n<\/tr>\n
    Kevesebb gyakoris\u00e1g\u00fa<\/td>\nMetabolic syndrome (glucose, lipids)<\/td>\nModerate — less than olanzapine \/ quetiapine; baseline + monitoring<\/td>\n<\/tr>\n
    Kevesebb gyakoris\u00e1g\u00fa<\/td>\nTard\u00edv dyskinesia<\/td>\nLower than first-generation antipsychotics; risk increases with duration<\/td>\n<\/tr>\n
    Kevesebb gyakoris\u00e1g\u00fa<\/td>\nQT-intervallum meghosszabbod\u00e1s<\/td>\nMild — less than ziprasidone<\/td>\n<\/tr>\n
    Ritka<\/td>\nNeuroleptic malignant syndrome<\/td>\nEmergency<\/td>\n<\/tr>\n
    Ritka<\/td>\nStroke \/ TIA in elderly<\/td>\nBlack-box dementia warning<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Gy\u00f3gyszerk\u00f6lcs\u00f6nhat\u00e1sok<\/h2>\n

    CYP2D6 substrate<\/strong>: levels rise with strong inhibitors (paroxetine, fluoxetine, bupropion, quinidine) — reduce dose. CYP3A4 inducers (carbamazepine, rifampin, phenytoin) lower levels — need higher dose.<\/p>\n

    Additive sedation \/ orthostasis<\/strong>: alcohol, benzodiazepines, opioids, antihypertensives.<\/p>\n

    QT-intervallum meghosszabbod\u00e1s<\/strong>: caution with citalopram (high dose), ondansetron, methadone.<\/p>\n

    Anti-Parkinson medications<\/strong>: antagonism — risperidone D2<\/sub> blockade reduces dopaminergic effect of levodopa, ropinirole, pramipexole.<\/p>\n

    Hyperprolactinaemia — the Risperidone Concern<\/h2>\n

    Risperidone is the most prolactin-elevating atypical antipsychotic<\/strong>. The mechanism is tuberoinfundibular D2<\/sub> blockade in the pituitary, which removes dopamine’s normal inhibition of prolactin release. Clinical consequences:<\/p>\n